Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment
13/06/2023 13:52
June 13 (Reuters) - OliX Pharmaceuticals Inc
226950.KQ :
* OLIX PHARMACEUTICALS ADMINISTERS FIRST PATIENT IN PHASE 1
CLINICAL STUDY OF RNAI THERAPEUTIC OLX72021 FOR ANDROGENIC
ALOPECIA
Source text for Eikon: ID:nBw1lJxTQa
Further company coverage: 226950.KQ
(reuters.briefs@thomsonreuters.com)
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment